<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6 ADVERSE REACTIONS<BR>               <BR>                  See peginterferon alfa and ribavirin Package Inserts for description of adverse reactions associated with their use.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia. (6.1) <BR>                        <BR><BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or <BR>                           <BR>                              www.fda.gov/medwatch.<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.1	Clinical Trials Experience<BR>                     <BR>                        Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of VICTRELIS cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<BR>                        The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:<BR>                        <BR>                           Anemia [see Warnings and Precautions (5.2) and Patient Counseling Information (17.2)]<BR>                           <BR>                           Neutropenia [see Warnings and Precautions (5.3) and Patient Counseling Information (17.3)]<BR>                           <BR>                           Hypersensitivity [see Contraindications (4), Warnings and Precautions (5.4) and Patient Counseling Information (17.4)]<BR>                           <BR>                        <BR>                        The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.<BR>                        The safety of the combination of VICTRELIS 800 mg three times daily with PegIntron/REBETOL was assessed in 2095 subjects with chronic hepatitis C in one Phase 2, open-label trial and two Phase 3, randomized, double-blind, placebo-controlled clinical trials. SPRINT-1 (subjects who were previously untreated) evaluated the use of VICTRELIS in combination with PegIntron/REBETOL with or without a four-week lead-in period with PegIntron/REBETOL compared to PegIntron/REBETOL alone. SPRINT-2 (subjects who were previously untreated) and RESPOND-2 (subjects who had failed previous therapy) evaluated the use of VICTRELIS 800 mg three times daily in combination with PegIntron/REBETOL with a four-week lead-in period with PegIntron/REBETOL compared to PegIntron/REBETOL alone [see Clinical Studies (14)]. The population studied had a mean age of 49 years (3% of subjects were older than 65 years of age), 39% were female, 82% were white and 15% were black.<BR>                        During the four week lead-in period with PegIntron/REBETOL in subjects treated with the combination of VICTRELIS with PegIntron/REBETOL, 28/1263 (2%) subjects experienced adverse reactions leading to discontinuation of treatment. During the entire course of treatment, the proportion of subjects who discontinued treatment due to adverse reactions was 13% for subjects receiving the combination of VICTRELIS with PegIntron/REBETOL and 12% for subjects receiving PegIntron/REBETOL alone. Events resulting in discontinuation were similar to those seen in previous studies with PegIntron/REBETOL. Only anemia and fatigue were reported as events that led to discontinuation in more than 1% of subjects in any arm.<BR>                        Adverse reactions that led to dose modifications of any drug (primarily PegIntron and REBETOL) occurred in 39% of subjects receiving the combination of VICTRELIS with PegIntron/REBETOL compared to 24% of subjects receiving PegIntron/REBETOL alone. The most common reason for dose reduction was anemia, which occurred more frequently in subjects receiving the combination of VICTRELIS with PegIntron/REBETOL than in subjects receiving PegIntron/REBETOL alone.<BR>                        Serious adverse events were reported in 11% of subjects receiving the combination of VICTRELIS with PegIntron/REBETOL and in 8% of subjects receiving PegIntron/REBETOL.<BR>                        Adverse events (regardless of investigator's causality assessment) reported in greater than or equal to 10% of subjects receiving the combination of VICTRELIS with PegIntron/REBETOL and reported at a rate of greater than or equal to 5% than PegIntron/REBETOL alone in SPRINT-1, SPRINT-2, and RESPOND-2 are presented in Table 3.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t3"><BR>                           <caption>Table 3 Adverse Events Reported in &#8805;10% of Subjects Receiving the Combination of VICTRELIS with PegIntron/REBETOL and Reported at a Rate of &#8805;5% than PegIntron/REBETOL alone</caption><BR>                           <col width="24%" align="left" valign="top"/><BR>                           <col width="19%" align="center" valign="middle"/><BR>                           <col width="19%" align="center" valign="middle"/><BR>                           <col width="19%" align="center" valign="middle"/><BR>                           <col width="19%" align="center" valign="middle"/><BR>                           <thead><BR>                              <tr styleCode="Botrule"><BR>                                 <th styleCode="Lrule Rrule">Adverse Events</th><BR>                                 <th styleCode="Rrule" colspan="2">Previously Untreated<br/>(SPRINT-1 &amp; SPRINT-2)</th><BR>                                 <th styleCode="Rrule" colspan="2">Previous Treatment Failures<br/>(RESPOND-2)</th><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <th styleCode="Lrule Rrule"/><BR>                                 <th styleCode="Rrule" colspan="2">Percentage of Subjects Reporting Adverse Events</th><BR>                                 <th styleCode="Rrule" colspan="2">Percentage of Subjects Reporting Adverse Events</th><BR>                              </tr><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule" valign="middle">Body System Organ Class</th><BR>                                 <th styleCode="Rrule">VICTRELIS + PegIntron + REBETOL<br/>(n=1225)</th><BR>                                 <th styleCode="Rrule">PegIntron + REBETOL<br/>(n=467)</th><BR>                                 <th styleCode="Rrule">VICTRELIS + PegIntron + REBETOL<br/>(n=323)</th><BR>                                 <th styleCode="Rrule">PegIntron + REBETOL<br/>(n=80)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Median Exposure (days)</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"><BR>                                    <content styleCode="bold">197</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"><BR>                                    <content styleCode="bold">216</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"><BR>                                    <content styleCode="bold">253</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"><BR>                                    <content styleCode="bold">104</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">Blood and Lymphatic System Disorders</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Anemia</td><BR>                                 <td styleCode="Rrule">50</td><BR>                                 <td styleCode="Rrule">30</td><BR>                                 <td styleCode="Rrule">45</td><BR>                                 <td styleCode="Rrule">20</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Neutropenia</td><BR>                                 <td styleCode="Rrule">25</td><BR>                                 <td styleCode="Rrule">19</td><BR>                                 <td styleCode="Rrule">14</td><BR>                                 <td styleCode="Rrule">10</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">Gastrointestinal Disorders</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Nausea</td><BR>                                 <td styleCode="Rrule">46</td><BR>                                 <td styleCode="Rrule">42</td><BR>                                 <td styleCode="Rrule">43</td><BR>                                 <td styleCode="Rrule">38</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Dysgeusia</td><BR>                                 <td styleCode="Rrule">35</td><BR>                                 <td styleCode="Rrule">16</td><BR>                                 <td styleCode="Rrule">44</td><BR>                                 <td styleCode="Rrule">11</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Diarrhea</td><BR>                                 <td styleCode="Rrule">25</td><BR>                                 <td styleCode="Rrule">22</td><BR>                                 <td styleCode="Rrule">24</td><BR>                                 <td styleCode="Rrule">16</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Vomiting</td><BR>                                 <td styleCode="Rrule">20</td><BR>                                 <td styleCode="Rrule">13</td><BR>                                 <td styleCode="Rrule">15</td><BR>                                 <td styleCode="Rrule">8</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Dry Mouth</td><BR>                                 <td styleCode="Rrule">11</td><BR>                                 <td styleCode="Rrule">10</td><BR>                                 <td styleCode="Rrule">15</td><BR>                                 <td styleCode="Rrule">9</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">General Disorders and Administration Site Conditions</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Fatigue</td><BR>                                 <td styleCode="Rrule">58</td><BR>                                 <td styleCode="Rrule">59</td><BR>                                 <td styleCode="Rrule">55</td><BR>                                 <td styleCode="Rrule">50</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Chills</td><BR>                                 <td styleCode="Rrule">34</td><BR>                                 <td styleCode="Rrule">29</td><BR>                                 <td styleCode="Rrule">33</td><BR>                                 <td styleCode="Rrule">30</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Asthenia</td><BR>                                 <td styleCode="Rrule">15</td><BR>                                 <td styleCode="Rrule">18</td><BR>                                 <td styleCode="Rrule">21</td><BR>                                 <td styleCode="Rrule">16</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">Metabolism and Nutrition Disorders</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Decreased Appetite</td><BR>                                 <td styleCode="Rrule">25</td><BR>                                 <td styleCode="Rrule">24</td><BR>                                 <td styleCode="Rrule">26</td><BR>                                 <td styleCode="Rrule">16</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Arthralgia</td><BR>                                 <td styleCode="Rrule">19</td><BR>                                 <td styleCode="Rrule">19</td><BR>                                 <td styleCode="Rrule">23</td><BR>                                 <td styleCode="Rrule">16</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">Nervous System Disorders</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Dizziness</td><BR>                                 <td styleCode="Rrule">19</td><BR>                                 <td styleCode="Rrule">16</td><BR>                                 <td styleCode="Rrule">16</td><BR>                                 <td styleCode="Rrule">10</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">Psychiatric Disorders</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Insomnia</td><BR>                                 <td styleCode="Rrule">34</td><BR>                                 <td styleCode="Rrule">34</td><BR>                                 <td styleCode="Rrule">30</td><BR>                                 <td styleCode="Rrule">24</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Irritability</td><BR>                                 <td styleCode="Rrule">22</td><BR>                                 <td styleCode="Rrule">23</td><BR>                                 <td styleCode="Rrule">21</td><BR>                                 <td styleCode="Rrule">13</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">Respiratory, Thoracic, and Mediastinal Disorders</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Dyspnea Exertional</td><BR>                                 <td styleCode="Rrule">8</td><BR>                                 <td styleCode="Rrule">8</td><BR>                                 <td styleCode="Rrule">11</td><BR>                                 <td styleCode="Rrule">5</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" colspan="5"><BR>                                    <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Alopecia</td><BR>                                 <td styleCode="Rrule">27</td><BR>                                 <td styleCode="Rrule">27</td><BR>                                 <td styleCode="Rrule">22</td><BR>                                 <td styleCode="Rrule">16</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Dry Skin</td><BR>                                 <td styleCode="Rrule">18</td><BR>                                 <td styleCode="Rrule">18</td><BR>                                 <td styleCode="Rrule">22</td><BR>                                 <td styleCode="Rrule">9</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Rash</td><BR>                                 <td styleCode="Rrule">17</td><BR>                                 <td styleCode="Rrule">19</td><BR>                                 <td styleCode="Rrule">16</td><BR>                                 <td styleCode="Rrule">6</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Other Important Adverse Reactions Reported in Clinical Trials<BR>                              <BR>                              Among subjects (previously untreated subjects or those who failed previous therapy) who received VICTRELIS in combination with peginterferon alfa and ribavirin, the following adverse drug reactions were reported. These events are notable because of their seriousness, severity, or increased frequency in subjects who received VICTRELIS in combination with peginterferon alfa and ribavirin compared with subjects who received only peginterferon alfa and ribavirin.<BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Gastrointestinal Disorders<BR>                                    <BR>                                    Dysgeusia (alteration of taste) was an adverse event reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin compared with subjects receiving peginterferon alfa and ribavirin alone (Table 3). Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Laboratory Values<BR>                              <BR>                              Changes in selected hematological parameters during treatment of adult subjects with the combination of VICTRELIS with PegIntron and REBETOL are described in Table 4.<BR>                              <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Hemoglobin<BR>                                    <BR>                                    Decreases in hemoglobin may require a decrease in dosage/interruption or discontinuation of ribavirin [see Warnings and Precautions (5.2) and Clinical Studies (14); see Package Insert for ribavirin]. If ribavirin is permanently discontinued, then peginterferon alfa and VICTRELIS must also be discontinued [see Dosage and Administration (2.3)].<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Neutrophils and Platelets <BR>                                    <BR>                                    The proportion of subjects with decreased neutrophil and platelet counts was higher in subjects treated with VICTRELIS in combination with PegIntron/REBETOL compared to subjects receiving PegIntron/REBETOL alone. Three percent of subjects receiving the combination of VICTRELIS with PegIntron/REBETOL had platelet counts of less than 50 × 109 per L compared to 1% of subjects receiving PegIntron/REBETOL alone. Decreases in neutrophils or platelets may require a decrease in dosage or interruption of peginterferon alfa, or discontinuation of therapy [see Package Inserts for peginterferon alfa and ribavirin]. If peginterferon alfa is permanently discontinued, then ribavirin and VICTRELIS must also be discontinued [see Dosage and Administration (2.3)].<BR>                                    <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t4"><BR>                                       <caption>Table 4 Selected Hematological Parameters</caption><BR>                                       <col width="24%" align="left" valign="top"/><BR>                                       <col width="19%" align="center" valign="middle"/><BR>                                       <col width="19%" align="center" valign="middle"/><BR>                                       <col width="19%" align="center" valign="middle"/><BR>                                       <col width="19%" align="center" valign="middle"/><BR>                                       <thead><BR>                                          <tr styleCode="Botrule"><BR>                                             <th styleCode="Lrule Rrule"/><BR>                                             <th styleCode="Rrule" colspan="2" valign="top">Previously Untreated<br/>(SPRINT-1 &amp; SPRINT-2)</th><BR>                                             <th styleCode="Rrule" colspan="2" valign="top">Previous Treatment Failures<br/>(RESPOND-2)</th><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <th styleCode="Lrule Rrule"/><BR>                                             <th styleCode="Rrule" colspan="2" valign="top">																Percentage of Subjects Reporting Selected Hematological Parameters 															</th><BR>                                             <th styleCode="Rrule" colspan="2" valign="top">																Percentage of Subjects Reporting Selected Hematological Parameters 															</th><BR>                                          </tr><BR>                                          <tr><BR>                                             <th styleCode="Lrule Rrule" valign="middle">																Hematological Parameters 															</th><BR>                                             <th styleCode="Rrule">																VICTRELIS + PegIntron + REBETOL<br/>(n=1225) 															</th><BR>                                             <th styleCode="Rrule">																PegIntron + REBETOL<br/>(n=467) 															</th><BR>                                             <th styleCode="Rrule">																VICTRELIS + PegIntron + REBETOL<br/>(n=323) 															</th><BR>                                             <th styleCode="Rrule">																PegIntron + REBETOL<br/>(n=80) 															</th><BR>                                          </tr><BR>                                       </thead><BR>                                       <tbody><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule" colspan="5"><BR>                                                <content styleCode="bold">Hemoglobin (g/dL) </content><BR>                                             </td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">&lt;10</td><BR>                                             <td styleCode="Rrule">49</td><BR>                                             <td styleCode="Rrule">29</td><BR>                                             <td styleCode="Rrule">49</td><BR>                                             <td styleCode="Rrule">25</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">&lt;8.5</td><BR>                                             <td styleCode="Rrule">6</td><BR>                                             <td styleCode="Rrule">3</td><BR>                                             <td styleCode="Rrule">10</td><BR>                                             <td styleCode="Rrule">1</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule" colspan="5"><BR>                                                <content styleCode="bold">Neutrophils (&#215; 10<sup>9</sup>/L)</content><BR>                                             </td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">&lt;0.75</td><BR>                                             <td styleCode="Rrule">31</td><BR>                                             <td styleCode="Rrule">18</td><BR>                                             <td styleCode="Rrule">26</td><BR>                                             <td styleCode="Rrule">13</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">&lt;0.5</td><BR>                                             <td styleCode="Rrule">8</td><BR>                                             <td styleCode="Rrule">4</td><BR>                                             <td styleCode="Rrule">7</td><BR>                                             <td styleCode="Rrule">4</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule" colspan="5"><BR>                                                <content styleCode="bold">Platelets (&#215; 10<sup>9</sup>/L)</content><BR>                                             </td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">&lt;50</td><BR>                                             <td styleCode="Rrule">3</td><BR>                                             <td styleCode="Rrule">1</td><BR>                                             <td styleCode="Rrule">4</td><BR>                                             <td styleCode="Rrule">0</td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td styleCode="Lrule Rrule">&lt;25</td><BR>                                             <td styleCode="Rrule">&lt;1</td><BR>                                             <td styleCode="Rrule">0</td><BR>                                             <td styleCode="Rrule">0</td><BR>                                             <td styleCode="Rrule">0</td><BR>                                          </tr><BR>                                       </tbody><BR>                                    </table><BR>                                 <BR><BR><BR><BR>                                 <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.2	Postmarketing Experience<BR>                     <BR>                        The following adverse reactions have been identified during post-approval use of VICTRELIS in combination with peginterferon alfa and ribavirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<BR>                        <BR>                           Gastrointestinal Disorders: mouth ulceration, stomatitis<BR>                        <BR>                           Skin and Subcutaneous Tissue Disorders: angioedema, urticaria [see Warnings and Precautions (5.4)]; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>